0001191638-14-000984.txt : 20140701 0001191638-14-000984.hdr.sgml : 20140701 20140701074602 ACCESSION NUMBER: 0001191638-14-000984 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140701 FILED AS OF DATE: 20140701 DATE AS OF CHANGE: 20140701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 14950727 BUSINESS ADDRESS: STREET 1: 2 KINGDOM STREET - LEGAL DEPARTMENT CITY: LONDON STATE: X0 ZIP: W2 6BD BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 2 KINGDOM STREET - LEGAL DEPARTMENT CITY: LONDON STATE: X0 ZIP: W2 6BD FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 azn201407016k.htm DIRECTOR/PDMR SHAREHOLDING azn201407016k.htm



FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of  July 2014

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 

 


Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
 
 
On 30 June 2014, Pascal Soriot, a Director of the Company, notified us that, on 30 June 2014, he purchased 46,200 AstraZeneca PLC Ordinary Shares of $0.25 each at a price of 4345 pence per share.
 
A C N Kemp
Company Secretary
1 July 2014

 
 

 
SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 01 July 2014
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary